US warns of cancer-agent in Japan weight loss pills

The US Food and Drug Administration on Tuesday warned consumers not to take a product called "Japan Rapid Weight Loss Diet Pills" because they contain a suspected cancer-causing agent.

The pills, advertised as promoting weight loss, are distributed by a company called Xiushentang and sold on popular web sites including Amazon.com, said the FDA.

Consumers are advised to stop using the pills -- which are packaged in three colors: green, yellow and blue -- and discard them. They should also see a doctor if they have experienced any side effects, the agency said.

An FDA lab analysis has confirmed that the pills, "Japan Rapid Weight Loss Diet Pills Green" contain "undeclared phenolphthalein," the agency said in a statement.

"Phenolphthalein is a solution used in chemical experiments and a suspected cancer-causing agent that is not approved for marketing in the United States."

The FDA has classified the agent as "not generally recognized as safe and effective," and it has been found to potentially damage or even cause mutations in a person's DNA, the warning said.

A similar notice was issued for "Japan Rapid Weight Loss Diet Pills Yellow" because they contain both phenolphthalein and sibutramine, a weight loss agent found in the drug Meridia that was removed from the market in 2010 because it boosted the risk of heart attack and stroke.

"The product poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or in some patients and may present a significant risk for patients with a history of , , arrhythmias or stroke," the FDA said.

A third product, "Japan Weight Loss Blue" contains sibutramine and ephedrine alkaloids. Products containing ephedra have been banned because they can boost blood pressure to risky levels.

The agency said the dangerous weight loss pills are part of an emerging trend in which companies sell products purporting to be dietary supplements but which contain hidden ingredients that can be harmful.

add to favorites email to friend print save as pdf

Related Stories

FDA declines to approve Orexigen diet drug

Feb 01, 2011

(AP) -- Orexigen Therapeutics Inc. shares plunged nearly 75 percent in pre-market trading Tuesday after U.S. health officials declined to approve the experimental weight loss pill Contrave.

Experimental diet pill shows promise, little risk

Jul 14, 2010

(AP) -- An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.

FTC sues Arizona company over acai pill free trials

Aug 16, 2010

(AP) -- The Federal Trade Commission says an Arizona company defrauded consumers who signed up for free trials of acai (ah-sah-EE') berry weight-loss pills and colon cleansing supplements.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

8 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.